Objective: To investigate if supplementation of preterm infant formula with a high docosahexaenoic acid/eicosapentaenoic acid (DHA/EPA) ratio together with a-linolenic acid (ALA) was able to maintain plasma and red blood cell DHA levels similar to that obtained with breast milk feeding without altering n-6 fatty acid status. Design and subjects: Preterm infants of mothers who elected not to breast feed (n ¼ 13) were assigned to ALA-and DHAenriched formula (DHA group: DHA/EPA ¼ 5/l). Infants fed breast milk (n ¼ 25) constituted a reference group (BM group). Anthropometric and fatty acid parameters (plasma phospholipids, cholesterol esters, triglycerides and red blood cell phosphatidylethanolamine, PL, CE, TG, RBC-PE, respectively) were obtained after 2 days (D2) and 15 days (D15) of enteral feeding and at the 37th week (W37) of post-conception age and 1 month later (W37+30) in the DHA group. Mean DHA intake ranged between 16.571.6 and 17.972.9 mg/kg/day between D2 and W37+30. Results: At W37, infant weights, heights, and head circumferences were similar in DHA and BM groups. PL DHA was maintained in the DHA group at the same level as in the BM group and the same for DHA in PE at W37. In RBC-PE and at W37, AA status was the same in both groups. In PL, AA levels remained very stable throughout the study; however, in the DHA group AA levels in PL remained in the range observed with standard formulas. Conclusion: The combined 18:3 n-3 and DHA supplementation of infant formula with DHA/EPA ratio 5/l is compatible with growth and n-3 fatty acid metabolism similar to that of preterm infants fed human milk.
Introduction
Early growth and development in mammals requires a significant supply of polyunsaturated fatty acids (PUFA) from n-3 and n-6 families during the foetal period (Martinez, 1992) as well as during the perinatal period (Clandinin et al, 1981) . n-3 fatty acid deficiency has been documented in animals and was associated with alterations in fatty acid composition, enzyme function and learning functions (Bourre et al, 1989) . Alterations in retinal, visual and processing functions have been reported in monkeys (Reisbick et al, 1996) . Analogous studies in preterm infants fed formulas with long-chain n-3 fatty acids compared to infants fed control formulas have reported better retinal function (Uauy et al, 1990) , visual acuity (Birch et al, 1992; Carlson et al, 1993) and processing speed (Uauy et al, 1990) with higher long-chain n-3 fatty acid status. Beneficial effects were also reported in term infants (Birch et al, 2000) . Levels of linoleic and linolenic acids remain stable in brain lipids during late gestation, whereas the long-chain PUFA (arachidonic (AA) and docosahexaenoic (DHA) acids) exhibit the greatest rise. DHA, in particular, increases markedly during brain growth. Accretion of these fatty acids also continues postnatally in human brain tissue (Clandinin et al, 1980) . After birth, preterm infants are deprived of intrauterine essential fatty acid supply from placental and maternal origins (Hornstra, 2000) . Moreover, the ability of desaturase activities to biosynthesise sufficient amounts of AA and DHA from linoleic and a -linolenic fatty acids remains either questionable (Carnielli et al, 1996) or unlikely since in vitro studies (Rodriguez et al, 1998a, b) in agreement with an in vivo study (Salem et al, 1996) have shown desaturase insufficiency especially during the last weeks of gestation. Thus, preterm infants require dietary supply of preformed long-chain PUFA in addition to parent essential fatty acids (Uauy et al, 1990) . Indeed, preterm infants, fed formulas containing sufficient amounts of linoleic and linolenic acids, but devoid of long-chain PUFA, rapidly exhibited declining plasma and red blood cell long-chain PUFA concentrations (Carlson et al, 1992) , especially a decreased DHA status which was associated with poorer retinal development and visual function (Uauy et al, 1990) . The importance of an adequate ratio between n-6/n-3 fatty acids has been pointed out .
We previously established that the supplementation of formula with a-linolenic acid (ALA) with a linoleic/alinolenic ratio of 6/l, a-linolenic acid being fixed at 0.8% of total energy, significantly improved the n-3 series PUFA status in plasma phospholipids and erythrocyte membranes in comparison with the control group of preterm infants fed regular formula (Billeaud et al, 1997) . However, this supplemented formula seemed to have reached the limit of alinolenic acid supplementation possibilities since the DHA levels did not reach those observed in infants fed human milk, justifying DHA supplementation.
Experiments in rodents and humans recently determined AA and DHA exchange rates between plasma and brain (Rapoport et al, 2001) . The data justify nutritional supplementation with DHA in order to increase plasma DHA and DHA brain supply. The availability of preparations containing high levels of DHA together with low levels of eicosapentaenoic acid (EPA) prompted us to evaluate DHA supplementation. Low EPA supply is very important since formula supplementation with common fish oils containing high levels of EPA significantly depressed the n-6 fatty acid pathway, resulting in lower AA in plasma phospholipids and erythrocyte membranes (Birch et al, 1992) and lower normalised body weight, length and head circumference (Carlson et al, 1992 ) when compared to breast-fed controls.
The objectives of this study were to evaluate the effects of a formula supplementation, characterised by a DHA/EPA ratio of 5/l on the DHA and AA status of preterm infants. For this purpose, plasma and erythrocyte fatty acid composition were compared between two groups of preterm infants: the first one received a DHA-enriched formula (DHA) together with ALA (66% in sn-2 position of triglycerides; Rietsh, 1982) and the second received breast milk (BM).
Methods

Subjects
This study, approved by the ethic committee of the University Hospital Center (CHU), included 38 infants from the Paediatric Department of University Hospital Center Arnaud de Villeneuve, Montpellier. Informed parental consent was obtained and new-borns were enrolled when the gestation age was less than 34 weeks, birth weight was above the 10th percentile of the national standard curves of birth weight, and clinical conditions permitted early oral feeding.
The infants were assigned to two groups: the DHA group (n ¼ 13) received a DHA-supplemented formula and the BM group (n ¼ 25) received breast milk (breast fed or breast fed plus lactarium milk).
In the DHA group, the mean clinical features of the infants were the following (means7s.d. and range): gestation age 31.371.2 weeks (30-33), birth weight 1455.47342.8 g (900-2120), birth height 39.972.9 cm (33-44) and head circumference 2871.7 cm (25-31.5). None had metabolic disorders or congenital malformations. In the BM group, the clinical features were gestation age 3172 weeks (28-34), weight 16397288 g (1090-2290), height 4272 cm (37-47) and head circumference 2972 cm (25-33).
Nutrient description
We used the same experimental formula (Pregallia+a-linolenic acid) as in the ONIDOL study (Billeaud et al, 1997) enriched with 100 mg of DHA/l (65 mg DHA/100 g dry milk), characterised by a DHA/EPA ratio of 5/l (Roche Vitamins Ltd, Basel, Switzerland). In this formula, ALA (0.6% of total energy) was from LEAR oil (low erucic acid rapeseed oil, 66% in sn-2 position of TG) and myristic acid (1.1% of total energy) was from milk fat (70% in sn-2 position of TG: Balcao et al, 1998) . Table 1 shows DHA intake during the study by the formula fed infants.
Study design
At birth, infants received intravenous solutions of glucoseelectrolytes-vitamins and proteins for 9.774.7 days (means7s.d.) of life but none received intravenous lipids. Then, the infants were studied at the second day (D2) (mean: 11.774.5 days of life, extreme value 5-19), the 15th day (D15) of formula or BM feeding and after about 5 weeks of formula or BM feeding, corresponding to the 37th week of post-conception age (W37). The study was ended 1 month later (W37+30) in the DHA group, but sampling at that time was not possible in the BM group (sampling at W37+30 was not designed at the beginning of the study in the BM group).
At D2, D15, W37 and W37+30 anthropometric measurements of crown-heel length, head circumference and body weight were recorded (Table 2 ) and a blood sample was collected.
Analytical methods
Blood samples (1-1.5 ml) were drawn into heparinised tubes and immediately centrifuged at 4000 Â g for 10 min. The plasma was collected and separated into several aliquots of 200 ml for fatty acid analysis. From the red blood cell pellet, 200 ml was washed twice with NaCl 9%, 1 mmol ethylenediaminetetraacetic acid. When, the plasma or red blood cell samples were not processed immediately, they were frozen and stored at À201C.
Fatty acid analysis in plasma lipid classes. Lipids were extracted from 200 ml of plasma by homogenising with 5 ml chloroform/methanol (2:1, v/v) and BHT was added to the solvent at a concentration of 1 mM (Folch et al. 1957) . Nonlipid contaminants were removed from the extracts by washing the organic phase with 0.5 ml KCl 0.15 M. The lipid extracts were concentrated under a stream of nitrogen and kept in 100 ml of chloroform/methanol (1:1, v/v). The lipid classes were separated by thin-layer chromatography (TLC) on Kieselgel 60 F 254 (Merck Darmstadt, Germany) with the solvent mixture hexane/diethylether/acetic acid (80:20:1, v/ v/v plus 20 mg BHT) (Merck Darmstadt, Germany). After a 30 min migration, the plates were sprayed with 2 0 ,7 0 dichlorofluorescein. The three plasma classes (phospholipids (PL), cholesterol esters (CE) and triglycerides (TG)) were identified under ultraviolet light by comparing their migration with authentic standards (Sigma, St Louis, USA). For technical reasons in the DHA group, one sample was lost at D15 and six at W37. For this reason, n ¼ l2 at D15 and n ¼ 7 at W37 instead of 13. The spots were removed by scraping and fatty acids were transesterified. The transesterification was carried out with a 45 min incubation in methanol/ sulphuric acid (19:1, v/v) at 901C, in the presence of the gel and with 6, 3.6 and 2.4 mg 21:0, as internal standard, for PL, CE and TG, respectively. After neutralising with sodium bicarbonate, the fatty acid methyl esters were extracted with 3 ml hexane and then separated and quantified using a DELSI DI 200 chromatograph (Delsi Nermag, Argenteuil, France) and a fused silica capillary column (50 m Â 0.32 mm, C.P. Sil 88, Chrompak, Les Ulis, France). Conditions were as follows: ionisation detector, 2501C; injector, 2301C; and oven program, 3.51C/min from 150 to 2301C. Hydrogen was used as the carrier gas with a flow rate of 1 ml/min. Quantitative analysis was achieved with reference to the internal standards using a DELSI ENICA 10 integrator. The percentage of total fatty acids was calculated by weight for the fatty acids of main interest.
Fatty acid analysis in red blood cells. The lipid extracts of 200 ml packed red blood cells were separated into PL classes by TLC as described above but using chloroform/methanol/ water (65:25:3, v/v/v) and BHT (1 mM) as the solvent system. Red blood cell phosphatidylethanolamine (RBC-PE) was identified and removed by the same technique. Fatty acids from RBC-PE, with 7.5 mg C21:0 as internal standard, were 
Statistical methods
The results of the descriptive statistics are given for each fraction in Tables 3-6 (PL-wt%, CE-wt%, TG-wt%, PE-wt%).
The significant difference between means of the BM and the DHA groups was evaluated by ANOVA for each fatty acid. Significant differences between BM vs DHA groups were also evaluated by t-test. These P-values should be considered as explorative due to the problem of multiple comparisons. Finally, for the two fatty acids of main interest, AA and DHA, an analysis of variance with repeated measures was Preterm infant formula with linolenic acid and DHA supplementation A Rodriguez et al performed in each fraction analysed with the between factor 'Treatment' (two groups: BM and DHA groups and the within factor 'Time' (three time points: D2, D15 and W37). A post hoc two-group comparison (Scheffé) was also performed. For all parameters, adjusted mean values were calculated for each diet and at each time of sampling (D2, D15, W37 and W37+30). The two-tailed level of significance was set at Po0.05. All data are presented as mean7s.d.
Results
The gestational ages of infants were 31.371.2 and 3172 weeks for the DHA and BM groups, respectively. Compared to the BM group, the birth weight of the group of infants fed DHA milk was lower (14557343 vs 16397288), probably because six infants of the DHA group (n ¼ 13) were two groups of triplets. In the DHA group, the mean duration of intravenous feeding was 15.6 days (8-26 days), significantly longer than in the BM groups (7 days). The DHA mean intake was 17.6 mg/kg/day in the study time period (D2 to W37+30) (Table 1 ) and the weight gain was 34 g/kg/day. Finally, the 37-week infant weights, heights and head circumferences were similar in the DHA group and in controls ( Table 2) .
PL fraction
Concerning the DHA (22:6 n-3) levels, Table 3 shows that no difference was observed between the BM and DHA groups throughout the study. In both groups, there was a slow increase with time. The same was observed for 22:5 n-3. The EPA (20:5 n-3) level slightly rose in the DHA group from 0.46 to 0.60% between D2 and W37 and was higher than in the BM group at each age. However, the EPA level remained lower than 0.70%, even at W37+30.
In the n-6 series, arachidonic acid (AA) (20:4 n-6) remained stable throughout the study in both groups, but the levels were significantly lower in the DHA group. It is important to notice that this difference was already observed at the beginning of the study and remained in the same range till W37. On the other hand, the levels of other n-6 fatty acids related to AA (20:3 n-6 and 22:5 n-6) were not significantly different in the BM and DHA groups either at D2 or at W37. Adrenic acid (22:4 n-6) was stable throughout the study in both groups but significantly lower in the DHA group.
The levels of the Mead acid (20:3 n-9) and of the palmitoleic acid (16:1 n-7), which are considered as good indicators of essential fatty acid deficiency, were three-fold lower at the end of the study in the DHA group (1.29% vs 0.44% and 0.70% vs 0.26% for 16:1 n-7 and 20:3 n-9, respectively). Interestingly, the 20:3 n-9 and 16:1 n-7 levels, which were significantly higher in the BM group than in the DHA group, decreased to the levels observed in the DHA group and no difference remained at W37. The same convergence was observed with 18:0 and 18:2 n-6 levels which were higher at D2 and D15 in the DHA group than in the BM group and decreased to almost the same value at W37.
CE fraction
DHA feeding resulted in a very positive significant effect on DHA (22:6 n-3) incorporation in plasma CE two-fold higher than the BM group at D2, D15 and W37, Po0.02 (Table 4) .
DHA supplementation did not affect AA (20:4 n-6) values in this fraction since there was no significant difference between groups at D15 and W37. In this fraction, 18:2 n-6 levels increased throughout the study in both feeding groups and were two-fold higher at W37+30 in the DHA group; meanwhile, we observed 18:1 n-9 and 16:1 n-7 decreases. Between D2 and W37, 16:1 n-7 decreased strongly from 10.7 and 10.1 to 4.3 and 4.6% in the BM and DHA groups, respectively.
TG fraction
The 18:3 n-3 levels in triglycerides were higher in the DHA group than in the BM group (0.78% vs 0.29% at D2, 0.92% vs 0.41% at D15 and 0.86% vs 0.63% at W37) (Table 5 ). This fatty acid increased over time in both groups. We observed that AA (20:4 n-6) levels in this fraction were lower in the DHA group compared to the BM group although this was only significant at W37. However, it should be observed that between D15 and W37+30, AA levels remained remarkably stable in the DHA group.
DHA (22:6 n-3) levels remained stable and no significant difference was observed between groups at D15 and at W37.
The 16:1 n-7 and the Mead acid (20:3 n-9) levels were reduced by half between D2 and W37 in the BM group and between D2 and W37+30 in the DHA group, showing a favourable evolution. Furthermore, the DHA/EPA ratio in this fraction was approximately equal to that of the DHA formula.
PE fraction
No significant change of DHA (22:6 n-3) level was observed in this fraction (Table 6 ). However, it should be noticed that the DHA level was significantly higher (about two-fold) in the DHA group than in the BM group, suggesting that DHA supplementation avoided the weakening observed at D15 in the BM group.
No significant change was observed in the AA (20:4 n-6) levels. Indeed, the AA level remained very stable during study in both the BM and DHA groups. The same was observed with 20:3 n-6, 22:4 n-6 and 22.5 n-6.
The 18:2 n-6 levels in PE increased from D2 to W37+30 (2.82% vs 4.59%) in the DHA group. EPA (20:5 n-3) levels were similar in the BM and DHA groups and remained lower than 1%, although this level markedly increased in the DHA group.
The levels of the deficiency marker (20:3 n-9) markedly decreased during the study, indicating a favourable evolution of PUFA status in the infants.
Discussion
Formula supplementation with fish oil containing lower amounts of DHA than EPA (DHA/EPA ratio B 2/3) resulted in lower growth parameters than in control preterm infants fed standard formula (Carlson et al, 1992) . These alterations of infant growth have been related to the presence of high levels of EPA in the diet. The present study shows that formula supplementation with a high DHA/EPA ratio (5/l) did not induce any adverse effect on infant growth. Indeed, EPA levels remained largely lower than 1% whatever the fraction considered, and in the BBC-PE fraction they did not significantly differ at any time between BM and DHA groups. The Mead acid and 16:1 n-7 largely decreased throughout the study in the four lipid fractions analysed and in both groups, suggesting a favourable processing of essential fatty acid metabolism. From the anthropometric point of view, it can be concluded that in the conditions used in the present study, a 17 mg/kg/day DHA intake satisfactorily supported the growth of premature new-borns (34 g/kg/day) during the first weeks of extrauterine life.
Considering fatty acids of the n-3 series in plasma PL, the main lipid fraction reflecting fatty acid metabolism, DHA levels did not significantly differ between the BM group and the DHA group at any timeFD2, D15 or W37. This clearly demonstrates that in the conditions used in our study, DHA supplementation maintained in premature new-borns the DHA status of infants fed breast milk. This conclusion is also supported by the DHA levels in RBC-PE plasma CE and plasma TG, though DHA levels were relatively low, as usually observed in these two latter plasma fractions. In plasma TG, 18:3 n-3 was higher in the DHA group than in the BM group (Table 5 ). This observation can be related to the exogenous supply of this fatty acid present in the supplemented formula. The same occurred in plasma CE and the difference was very significant at each time point, in agreement with the observation that 18:3 n-3 in CE reflects the nutritional intake of this fatty acid in infants (Babin et al, 2000) .
Maintenance of AA status and n-6 fatty acid metabolism is a major concern when n-3 fatty acid supplementation is used in new-borns. Considering RBC-PE and plasma CE, AA status was the same in BM and DHA groups at W37. These data were confirmed by the pattern of the parent fatty acids of the n-6 series: the precursor 20:3 n-6, the higher metabolite 22:5 n-6 and 22:4 n-6, a potential supply of AA by retroconversion. Throughout the study, these three fatty acids were maintained in RBC-PE at the same level in the DHA group as in the BM group or even higher. Finally, it is of special interest to notice that at W37 in RBC-PE, the levels of the main three long-chain PUFAs of brain tissueFAA, adrenic acid and DHAFwere slightly higher in the DHA group than in the BM group, that the ratio adrenic acid/DHA was remarkably stable (about 1) and that the level of adrenic acid (6.1%) was the same as in the cortex of breast-fed infants of the same age (2-48 weeks) . In the same way, when considering plasma PL fatty acids, 20:3 n-6 and 22:5 n-6 were the same in BM and in DHA groups at W37. In the same lipid fraction, AA levels were remarkably stable throughout the study but significantly lower in the DHA group than in the BM group. Taken together, the data suggest that the significant difference observed in PL fraction between BM and DHA groups could be related to the lower AA level found in the DHA group at the beginning of the study (D2). However, a recent intervention study (Lapillonne et al, 2000) using a low EPA fish oil supplementation with lower a-linolenic supply, but for a longer period, reported lower AA RBC-PL in the DHA-supplemented group than in the breast-fed group.Unfortunately, plasma PL are not available in this report. Considering the metabolic turn-over of plasma PL and of RBC-PL, it is clear that metabolic alterations should first appear in plasma PL. Anyway, taken together, the data of both studies draw attention to significant differences occurring in AA status: one in plasma PL and the other in RBC-PE. AA status was maintained in two recent intervention trials with both AA and DHA supplementation (Clandinin et al, 1999 , Birch et al, 2000 but not with 18:3 n-6 supplementation (Demmelmair et al, 2001) .
In conclusion, the data suggest that combined 18:3 n-3 and DHA supplementation of infant formula with DHA/EPA ratio 5/l is compatible with normal growth and n-3 fatty acid metabolism in premature new-borns. As far as DHA is concerned, DHA values obtained with the combined association used in the present study were closer to that of the BM group than DHA values previously obtained with a single 18:3 n-3 supplementation (Billeaud et al, 1997) , justifying DHA supplementation in preterm infant formula. Moreover, the AA levels in the DHA groups were similar to the levels obtained with infant formulas rich in either 18:2 n-6 or 18:3 n-3 (Billeaud et al, 1997) .
